Zymeworks, Inc.

Who: Roche and Oxford BioTherapeutics What: The Swiss major has entered into a multi-year collaboration with OBT to develop first-in-class antibody-based therapeutics for the treatment of cancer.

The US Food and Drug Administration’s expectations for the timing of accelerated approval confirmatory trials came into clearer focus in 2024 with new policy documents and real-world examples. The age

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Acepodia is emerging as one of the world’s few developers of antibody-drug conjugates (ADCs) preparing to advance into the clinic with a dual payload-fixed design of targeted cancer therapy. Based out